Up-regulation of liver Pcsk9 gene expression as a possible cause of hypercholesterolemia in experimental chronic renal failure

Molecular and Cellular Biochemistry

Volumn 411, Issue 1-2, 2016, Pages 281-287

  Sucajtys Szulc, Elzbieta ^a   Szolkiewicz, Marek ^a   Swierczynski, Julian ^a   Rutkowski, Boleslaw ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

CRF; Hypercholesterolemia; LDL; LDL R; PCSK9; SREBF 2

Indexed keywords

BETA ACTIN; CREATININE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; UNCLASSIFIED DRUG; PCSK9 PROTEIN, RAT; PROPROTEIN CONVERTASE 9;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA ACTIN GENE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DYSLIPIDEMIA; ENZYME BLOOD LEVEL; GENE; GENE EXPRESSION REGULATION; HYPERCHOLESTEROLEMIA; MALE; NONHUMAN; PCSK9 GENE; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; SREBF 2 GENE; UPREGULATION; WESTERN BLOTTING; ANIMAL; ENZYMOLOGY; GENETICS; LIVER; METABOLISM; WISTAR RAT;

ANIMALS; HYPERCHOLESTEROLEMIA; LIVER; MALE; PROPROTEIN CONVERTASE 9; RATS; RATS, WISTAR; RNA, MESSENGER; SERINE ENDOPEPTIDASES; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; UP-REGULATION;

EID: 84957433595     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-015-2590-0     Document Type: Article

References (28)

1. Oda H, Keane WF (1998) Lipid abnormalities in end stage renal disease. Nephrol Dial Transplant 13(Suppl 1):45–49
2. Sun L, Halaihel N, Zhang W, Rogers T, Levi M (2002) Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem 277:18919–18927
3. Szolkiewicz M, Sucajtys E, Chmielewski M, Wolyniec W, Rutkowski P, Boguslawski W, Swierczynski J, Rutkowski B (2002) Increased rate of cholesterologenesis—a possible cause of hypercholesterolemia in experimental chronic renal failure in rats. Horm Metab Res 34:234–237
4. Chmielewski M, Sucajtys E, Swierczynski J, Rutkowski B, Bogusławski W (2003) Contribution of increased Hmg-CoA reductase gene expression to hypercholesterolemia in experimental chronic renal failure. Mol Cell Biochem 246:187–191
5. Chmielewski M, Sucajtys-Szulc E, Kossowska E, Swierczynski J, Rutkowski B, Boguslawski W (2007) Increased gene expression of liver Srebp-2 in experimental chronic renal failure. Atherosclerosis 191:326–332
6. Lopez D (2008) PCSK9: an enigmatic protease. Biochim Biophys Acta 1781:184–191
7. Lambert G, Charlton F, Rye KA, Piper DE (2009) Molecular basis of PCSK9 function. Atherosclerosis 203:1–7
8. Lambert G, Sjouke B, Choque B, Kastelein J, Hovingh GK (2012) The PCSK9 decade. J Lipid Res 53:2515–2524
9. Stein EA, Swergold GDP (2013) Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics. Curr Atheroscler Rep 15:310. doi:10.1007/s11883-013-0310-3
10. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chretien M (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA 100:928–933
11. Seidah NG, Prat A (2007) The proprotein convertases are potential targets in the treatment of dyslipidemia. J Mol Med (Berl) 85:685–696
12. Urban D, Poss J, Bohm M, Laufs U (2013) Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol 62:1401–1408
13. Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, Hammer RE, Moon YA, Horton JD (2005) Decreased plasma cholesterol and hypersensitivity to statins in mice lacking PCSK9. Proc Natl Acad Sci USA 102:5374–5379
14. Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, Seidah NG, Prat A (2008) Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 48:646–654
15. Alborn WE, Cao G, Careskey HE, Qian YW, Qian YW, Subramaniam DR, Davies J, Conner EM, Konrad RJ (2007) Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem 53:1814–1819
16. Lee ChJ, LeeY-ho Parc SW, Kim KJ, Park S, Youn J-Ch, LeeS-H Kang S-M, Jang Y (2013) Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects. Metabolism 62:845–850
17. Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM, Stein EA (2014) DESCARTES investigators: a 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 370:1809–1819
18. Jin K, Park BS, Kim YW, Vaziri ND (2014) Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study. Am J Kidney Dis 63:584–589
19. Liu S, Vaziri ND (2014) Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome. Nephrol Dial Transplant 29:538–543
20. Konarzewski M, Szolkiewicz M, Sucajtys-Szulc E, Blaszak J, Lizakowski S, Swierczynski J, Rutkowski B (2014) Elevated circulating PCSK-9 concentration in renal failure patients is corrected by renal replacement therapy. Am J Nephrol 40:157–163
21. Jeong HJ, Lee HS, Kim KS, Kim YK, Yoon D, Park SW (2008) Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J Lipid Res 49:399–409
22. Costet P, Cariou B, Lambert G, Lalanne F, Lardeux B, Jarnoux AL, Grefhorst A, Staels B, Krempf M (2006) Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem 281:6211–6218
23. Swierczynski J, Korczynska J, Szolkiewicz M, Karbowska J, Kochan Z, Nieweglowski T, Kusiak E, Rutkowski B (2001) Low leptin mRNA level in adipose tissue and normoleptinemia in experimental chronic renal failure. Exp Nephrol 9:54–59
24. Turyn J, Stojek M, Swierczynski J (2010) Up-regulation of stearol-CoA desaturase 1 and elongase 6 genes expression in rat lipogenic tissues by chronic food restriction and chronic food restriction/refeeding. Mol Cell Biochem 345:181–188
25. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159
26. Winer J, Jung CK, Shackel I, Williams PM (1999) Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 270:41–49
27. Roubtsova A, Munkonda MN, Awan Z, Marcinkiewicz J, Chamberland A, Lazure C, Cianflone K, Seidah NG, Prat A (2011) Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol 31:785–791
28. Kwakernaak AJ, Lambert G, Slagman MC, Waanders F, Laverman GD, Petrides F, Dikkeschei BD, Navis G, Dullaart RP (2013) Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment. Atherosclerosis. 226:459–465